providing special products to special people

• Home
• About Us
  • Corporate Strategy
  • Organization
  • Management
    • Experience
  • Supervisory Board
  • Investors
• Products
  • Dantrium^® / Dantrolen^®
  • Savene^®
  • MuGard™
  • Xerotin^®
• Business Development
  • Partnerships
• Careers
• Press Room
• Contacts
• Legal Disclaimer

• 04/03/2010

  SpePharm announces the acquisition of Savene from TopoTarget,

• 20/04/2009

  SpePharm announces the European launches of two new products: MuGard^® and Xerotin^®

• 14/04/2009

  SpePharm announces a claim in excess of €35 M against BioAlliance Pharma for breaking up their Joint-Venture SpeBio

Information on
Dantrium / Dantrolen »
Informationen zu
Dantrium / Dantrolen »
Informaciones sobre
Dantrium / Dantrolen »
A propos du
Dantrium / Dantrolène »
Informazioni su
Dantrium / Dantrolen »

Legal Disclaimer

Responsible for the content: webmaster@spepharm.com

SpePharm Holding BV
Registered office: Kingsfordweg 151, 1043 GR Amsterdam, The Netherlands
Company Registration No: 3211 7318 KVK AMSTERDAM
Registered in The Netherlands

SpePharm SAS France
Registered office: 39 Boulevard Malesherbes, 75008 Paris, France
Company Registration No: 493 338 453 R.C.S. PARIS
Registered in France

providing special products to special people

“SpePharm” is the registered trade-mark of SpePharm IP BV.